Searched for
MEL SPIGELMAN
WHO: Tuberculosis cases rise for the first time in yearsThe COVID-19 pandemic disrupted services for people with TB along with many other health programs. WHO said many people went undiagnosed, n...- Urgency lacking as TB passes Covid as biggest killer: ExpertTuberculosis, once called consumption, was the world's biggest infectious killer before the arrival of Covid-19, with 1.5 million people dy...
- TB Alliance in talks with government over use of new shorter BPaL RegimenIndia has the world's highest TB burden-- 2.6 million active cases and close to 450,000 deaths each year from the infectious bacterial dise...
- Lupin, TB Alliance join hands for new therapy for drug-resistant tuberculosisTB Alliance President and CEO Mel Spigelman said that partnering with Lupin -- a well-established manufacturer with experience delivering h...
- BPaL regimen can cut time for treatment of drug-resistant TBBPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB...
- Mylan gets DCGI nod for anti-tuberculosis drug Pretomanid for conditional accessThe Drug Controller General of India (DCGI) has approved Pretomanid for conditional access under the National Tuberculosis Elimination Prog...
- Mumbai pharma company gets licence for breakthrough TB drugA global non-profit drug developer TB Alliance has tied up with domestic company Macleods Pharmaceuticals to develop and commercialise its ...
- States must invest in R&D to fund new drug discoveries: TB AllianceGeneric manufacturers are essential players in the fight to end TB so we do speak with generic manufacturers as part of our access strategy.
- Drug combo speeds up TB treatmentThe drug combination, known as PaMZ, killed more bacteria than standard treatment and was effective in treating drug-resistant tuberculosis.
Load More
